Author's response to reviews

Title: P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

Authors:

Ruoping Tang (ruoping.tang@htd.aphp.fr)
Simy Cohen (simyalice@yahoo.fr)
Jean-Yves Perrot (jean-yves.perrot@htd.aphp.fr)
Anne-Marie Faussat (Anne-Marie.Faussat@ifr58.bhdc.jussieu.fr)
Claudia Zuany-Amorim (Claudia.Fromond@sanofi-aventis.com)
Zora Marjanovic (zora.marjanovic@htd.aphp.fr)
Hamid Morjani (hamid.morjani@univ-reims.fr)
Ollivier Legrand (ollivier.legrand@htd.aphp.fr)
Jean-Pierre Marie (jean-pierre.marie@htd.aphp.fr)
Elise Corre (corre.elise@yahoo.fr)
Fanny Fava (fava.fanny@yahoo.fr)

Version: 4 Date: 14 May 2009

Author's response to reviews: see over
Dear Editor,

For

MS: 3838860542207331
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
Ruoping Tang, Simy Cohen, Jean-Yves Perrot, Anne-Marie Faussat, Claudia Zuany-Amorim1, Zora Marjanovic, Hamid Morjani2, Fanny Fava, Elise Corre, Ollivier Legrand and Jean-Pierre Marie

Following your suggestions, we have one more time revised our manuscript for ensuring that our manuscript conforms to all of the points.

We have added in methods:

Ethical approval

The present study carried out on human blood cells is in compliance with the Helsinki Declaration, and was approved by the French Institute National of Cancer ("Tumorothèque Leucémies" Hôtel-Dieu N°579). AML patient blood samples were obtained after their informed consent (Formulary EORTC study N° 06012).

Sincerely yours,

Dr Ruoping TANG